MX2013011721A - Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. - Google Patents

Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2013011721A
MX2013011721A MX2013011721A MX2013011721A MX2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A
Authority
MX
Mexico
Prior art keywords
masp
complement activation
dependent complement
methods
dependent
Prior art date
Application number
MX2013011721A
Other languages
English (en)
Other versions
MX339002B (es
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Tom Dudler
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2013011721A publication Critical patent/MX2013011721A/es
Publication of MX339002B publication Critical patent/MX339002B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

En un aspecto, la invención proporciona métodos para inhibir los efectos de la activación de complemento dependiente de MASP-2 en un sujeto vivo. Los métodos comprenden los pasos de administrar, a un sujeto en necesidad del mismo, una cantidad eficaz de un agente inhibidor de MASP-2 para inhibir la activación del complemento dependiente de MASP-2. En algunas modalidades, el agente inhibidor de MASP-2 inhibe la lesión celular asociada con la activación de la vía del complemento alternativa mediada por MASP-2, mientras deja al componente de la vía clásica (dependiente de C1q) intacta. En otro aspecto, la invención proporciona composiciones para inhibir los efectos de la activación de complemento dependiente de lectina, comprendiendo una cantidad terapéuticamente eficaz de un agente inhibidor de MASP-2 y un vehículo farmacéuticamente aceptable.
MX2013011721A 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. MX339002B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473698P 2011-04-08 2011-04-08
PCT/US2012/032650 WO2012139081A2 (en) 2011-04-08 2012-04-06 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (2)

Publication Number Publication Date
MX2013011721A true MX2013011721A (es) 2014-03-05
MX339002B MX339002B (es) 2016-05-06

Family

ID=46966283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011721A MX339002B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2016006039A MX355648B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016006039A MX355648B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Country Status (18)

Country Link
US (5) US8951522B2 (es)
EP (3) EP3964233A1 (es)
JP (4) JP5937197B2 (es)
KR (6) KR101720562B1 (es)
CN (3) CN103781492A (es)
AU (1) AU2012239889B2 (es)
BR (1) BR112013025917A2 (es)
CA (4) CA2832187C (es)
CL (1) CL2013002874A1 (es)
DK (2) DK2694108T3 (es)
ES (2) ES2894342T3 (es)
HK (1) HK1250342A1 (es)
IL (3) IL228758B (es)
MX (2) MX339002B (es)
NZ (5) NZ617298A (es)
PL (1) PL3287142T3 (es)
RU (2) RU2662563C2 (es)
WO (1) WO2012139081A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
KR101720562B1 (ko) 2011-04-08 2017-03-30 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
DK3366307T3 (da) * 2012-04-06 2021-11-01 Omeros Corp Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
NZ629473A (en) * 2012-06-18 2017-02-24 Univ Leicester Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
AU2013334229B2 (en) * 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) * 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
RU2020111211A (ru) * 2013-10-17 2021-11-08 Омерос Корпорейшн Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
WO2015070041A1 (en) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ra Pharmaceuticals, Inc. Modulation of complement activity
HUE056613T2 (hu) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Komplementaktivitás modulátorai
IL254670B2 (en) 2015-04-06 2023-04-01 Bioverativ Usa Inc Human anti-c1s antibodies and methods of using them
SG10202011469UA (en) * 2015-11-09 2020-12-30 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
HUE061759T2 (hu) 2015-12-16 2023-08-28 Ra Pharmaceuticals Inc Komplement aktivitás modulátorai
HUE056019T2 (hu) 2015-12-23 2022-01-28 eleva GmbH Polipeptidek komplement aktiváció gátlására
JP6682653B2 (ja) 2016-01-05 2020-04-15 ユニバーシティー オブ レスター 線維症の阻害を必要とする対象において線維症を阻害するための方法
US10870708B2 (en) * 2016-03-31 2020-12-22 University Of Leicester Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP6442703B2 (ja) * 2016-12-26 2018-12-26 日本ビーシージー製造株式会社 細菌細胞壁骨格成分を含有する水中油型エマルション製剤
CN110506116A (zh) * 2017-03-09 2019-11-26 协和麒麟株式会社 抑制masp2表达的核酸
AU2018306411B2 (en) * 2017-07-28 2022-03-31 Lemonex Inc. Pharmaceutical composition for preventing or treating liver cancer
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
PE20211869A1 (es) * 2018-11-15 2021-09-21 Ionis Pharmaceuticals Inc Moduladores de la expresion de irf5
US20230272402A1 (en) * 2018-12-25 2023-08-31 Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
US20220162607A1 (en) * 2019-03-14 2022-05-26 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
EP3947352A1 (en) 2019-03-29 2022-02-09 RA Pharmaceuticals, Inc. Complement modulators and related methods
CA3137895A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
EP3974533A4 (en) * 2019-05-22 2023-11-08 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD AND USE
CN111024947A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 白色念珠菌荧光免疫层析测定试剂盒及其制备方法
WO2021107057A1 (ja) 2019-11-27 2021-06-03 京セラ株式会社 通信制御方法及びユーザ装置
CN115103709A (zh) 2019-12-04 2022-09-23 奥默罗斯公司 Masp-2抑制剂和使用方法
EP4069678A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
US20210179612A1 (en) 2019-12-04 2021-06-17 Omeros Corporation Masp-2 inhibitors and methods of use
EP4107165A1 (en) * 2020-02-19 2022-12-28 Alnylam Pharmaceuticals, Inc. Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
CN113674860B (zh) * 2020-05-15 2024-05-17 北京大学人民医院 一种难治性iTTP风险预测装置、系统及其应用
KR20240000543A (ko) * 2021-04-25 2024-01-02 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-masp2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2024026258A2 (en) * 2022-07-25 2024-02-01 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AR243935A1 (es) 1987-12-15 1993-09-30 Gene Shears Pty Ltd Compuesto oligonucleotidico de aplicacion biologica en plantas y excluyendo su uso farmaceutico, metodo para prepararlo y composicion que lo comprende.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2689694A1 (en) 1999-07-21 2001-02-01 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
CA2391402A1 (en) 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1303591B1 (en) 2000-07-13 2009-06-24 Helion Biotech ApS Masp-2, a complement-fixing enzyme, and uses for it
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
JP2005519917A (ja) 2002-02-01 2005-07-07 オメロス コーポレイション 軟骨分解の全身阻害のための組成物および方法
AU2003223288A1 (en) 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
CN101327325A (zh) 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
ITRM20020511A1 (it) * 2002-10-09 2004-04-10 Santa Anna Acuto Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi.
EP1570075A2 (en) 2002-12-03 2005-09-07 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2004083250A1 (ja) * 2003-03-17 2004-09-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物
EP1625166B1 (en) 2003-05-12 2015-04-08 Helion Biotech ApS Antibodies to masp-2
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
TR201708554T4 (tr) 2004-06-10 2019-02-21 Omeros Corp Masp-2 ye bağlı tamamlayıcı aktivasyon ile ilişkili durumların tedavisi için yöntemler.
ATE544866T1 (de) * 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
CA2640167A1 (en) 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
AU2007223796B2 (en) 2006-03-08 2013-01-24 Iveric Bio., Inc. Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
EP3101031A1 (en) * 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
JP2012533288A (ja) 2009-07-17 2012-12-27 リグショスピタレト 補体活性化の阻害剤
WO2011047346A1 (en) 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EA201290286A1 (ru) * 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
SG183541A1 (en) 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101720562B1 (ko) 2011-04-08 2017-03-30 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
CA3025762C (en) 2011-05-04 2021-11-09 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
NZ629473A (en) 2012-06-18 2017-02-24 Univ Leicester Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
RU2020111211A (ru) 2013-10-17 2021-11-08 Омерос Корпорейшн Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
SG10202011469UA (en) 2015-11-09 2020-12-30 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
WO2018070521A1 (ja) * 2016-10-14 2018-04-19 公立大学法人福島県立医科大学 補体の活性化経路を阻害する融合ポリペプチド

Also Published As

Publication number Publication date
PL3287142T3 (pl) 2021-12-27
HK1250342A1 (zh) 2018-12-14
EP3287142A1 (en) 2018-02-28
CA2977009A1 (en) 2012-10-11
AU2012239889A1 (en) 2013-03-14
MX339002B (es) 2016-05-06
DK2694108T3 (en) 2018-08-20
CN107638565B (zh) 2021-12-21
US20170166658A1 (en) 2017-06-15
CA2832187C (en) 2017-10-10
ES2894342T3 (es) 2022-02-14
WO2012139081A2 (en) 2012-10-11
KR20170034941A (ko) 2017-03-29
JP2018024698A (ja) 2018-02-15
DK3287142T3 (da) 2021-11-01
US10202465B2 (en) 2019-02-12
CN103781492A (zh) 2014-05-07
CA3076975A1 (en) 2012-10-11
NZ617298A (en) 2015-08-28
IL274206A (en) 2020-06-30
JP6893539B2 (ja) 2021-06-23
KR20190142445A (ko) 2019-12-26
IL228758B (en) 2019-12-31
CA2977009C (en) 2020-05-05
KR101720562B1 (ko) 2017-03-30
KR20220044616A (ko) 2022-04-08
JP5937197B2 (ja) 2016-06-22
IL264172B (en) 2022-04-01
CN110075294A (zh) 2019-08-02
AU2012239889B2 (en) 2015-09-03
JP2014512363A (ja) 2014-05-22
KR101870915B1 (ko) 2018-06-25
JP2019214616A (ja) 2019-12-19
EP3287142B1 (en) 2021-08-04
RU2018125514A (ru) 2019-03-12
WO2012139081A3 (en) 2012-11-29
EP3964233A1 (en) 2022-03-09
IL228758A0 (en) 2013-12-31
CL2013002874A1 (es) 2014-03-07
IL264172A (en) 2019-02-28
NZ731596A (en) 2022-07-01
CA3237802A1 (en) 2012-10-11
JP2016185966A (ja) 2016-10-27
CA2832187A1 (en) 2012-10-11
EP2694108A2 (en) 2014-02-12
MX355648B (es) 2018-04-26
KR20140009472A (ko) 2014-01-22
NZ746139A (en) 2023-11-24
ES2683307T3 (es) 2018-09-26
RU2743409C2 (ru) 2021-02-18
RU2662563C2 (ru) 2018-07-26
JP6239030B2 (ja) 2017-11-29
NZ717517A (en) 2017-07-28
EP2694108B1 (en) 2018-06-06
US20120258095A1 (en) 2012-10-11
KR102217658B1 (ko) 2021-02-22
EP2694108A4 (en) 2014-10-01
US20150239985A1 (en) 2015-08-27
KR20180072851A (ko) 2018-06-29
RU2013149792A (ru) 2015-05-20
KR20210021101A (ko) 2021-02-24
US8951522B2 (en) 2015-02-10
JP6584476B2 (ja) 2019-10-02
RU2018125514A3 (es) 2019-10-30
BR112013025917A2 (pt) 2016-12-20
CN107638565A (zh) 2018-01-30
US20190292272A1 (en) 2019-09-26
US20220089781A1 (en) 2022-03-24
NZ709997A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
MX2013011721A (es) Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2012004343A (es) Metodos para el tratamiento de la coagulacion intravascular diseminada mediante la inhibicion de la activacion del complemento dependiente de la masp-2.
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
MX2022005200A (es) Composiciones y metodos para modular la expresion de angiotensinogeno.
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
NZ742987A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
PH12020500276A1 (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
WO2012078633A8 (en) Methods of inhibiting metastasis from cancer
MX2018008658A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/ o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
MX2017011018A (es) Inhibicion de la actividad de olig2.
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
WO2012158776A3 (en) Combination therapy for treatment of cancer
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.

Legal Events

Date Code Title Description
FG Grant or registration